Table 3.
Medical costs and resource utilization from date of transplant hospitalization to day 100 post-transplantation
| Cost category | Transplant Type | ||
|---|---|---|---|
| Autologous HCT | Allogeneic HCT | Not Specified* | |
| Sample size | 1678 | 1320 | 367 |
| Number of hospitalizations, median (range)† | 1 (1–8) | 1 (1–7) | 1 (1–6) |
| Number of hospitalizations, N (%) | |||
| 1 (HCT hospitalization) | 1275 (76.0) | 759 (57.5) | 254 (69.2) |
| 2 | 301 (17.9) | 370 (28.0) | 75 (20.4) |
| 3 | 69 (4.1) | 136 (10.3) | 26 (7.1) |
| ≥4 | 33 (2.0) | 55 (4.2) | 12 (3.3) |
| Total days hospitalized, median (IQR) | 19 (15–23) | 31 (23–45) | 20 (6–30) |
| Total days hospitalized, N (%) | |||
| ≤15 | 433 (25.8) | 125 (9.5) | 132 (36.0) |
| 16–30 | 1033 (61.6) | 523 (39.6) | 145 (39.5) |
| 31–60 | 180 (10.7) | 519 (39.3) | 76 (20.7) |
| ≥61 | 32 (1.9) | 153 (11.6) | 14 (3.8) |
| Number of outpatient clinic visits, median (range) | 12 (8–19) | 22 (13–32) | 13 (8–25) |
| Number of outpatient clinic visits, N (%) | |||
| ≤10 | 714 (42.6) | 267 (20.2) | 140 (38.2) |
| 11–20 | 599 (35.7) | 349 (26.4) | 110 (30.0) |
| 21–30 | 238 (14.2) | 344 (26.1) | 70 (19.1) |
| 31–40 | 95 (5.7) | 189 (14.3) | 26 (7.1) |
| ≥40 | 32 (1.9) | 171 (13.0) | 21 (5.7) |
| Total costs, median (IQR) | $99,899 (73,914–140,555) | $203,026 (141,742–316,426) | $106,782 (54,728–198,963) |
| Total outpatient costs, median (IQR) | $7,462 (3,079–16,038) | $20,767 (8,898–41,271) | $7,829 (1,771–22,756) |
| Total inpatient costs, median (IQR) | $88,429 (62,828–123,328) | $174,398 (116,996–269,129) | $90,000 (51,994–170,553) |
| Costs for HCT hospitalization, median (IQR) | $82,606 (59,165–110,881) | $151,899 (106,438–233,282) | $82,641 (46,377–145,326) |
| Costs for subsequent hospitalization, median (IQR)‡ | $0 (0-0) | $0 (0–22,585) | $0 (0–7,940) |
HCT – hematopoietic cell transplantation; IQR – interquartile range
*
Graft source could not be ascertained from claims data
†
Includes hospitalization for HCT
‡
Shows costs for subsequent hospitalization for all patients in the cohort (subsequent hospitalization costs for patients who did not require hospitalization after the initial inpatient stay for HCT were considered to be $0); median costs for patients who received a subsequent hospitalization were as follows – autologous HCT (N=403) $17,425 (IQR, 9,414–46,953), allogeneic HCT (N=561) $30,561 (IQR, 13,484–89,805), not specified (N=113) $28,004 (IQR, 11,438–25,066)